FDA Expands Indication for Amivantamab in Lung Cancer ...Middle East

Amivantamab plus chemo is now indicated in locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations after disease progression on or after an EGFR-TKI. Medscape Medical News

Read More Details
Finally We wish PressBee provided you with enough information of ( FDA Expands Indication for Amivantamab in Lung Cancer )

Also on site :

• Morning Report — Texas braces for more flood danger after Hill Country tragedy 
• Bangladesh lawyers challenge ex-PM Hasina’s murder trial charges
• Ukraine plagued by ‘palace politics’ and purges – Economist